simvastatin has been researched along with Disease Exacerbation in 130 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (8.46) | 18.2507 |
| 2000's | 50 (38.46) | 29.6817 |
| 2010's | 61 (46.92) | 24.3611 |
| 2020's | 8 (6.15) | 2.80 |
| Authors | Studies |
|---|---|
| Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA | 1 |
| Carroll, C; Chapman, R; Cocking, L; Creanor, S; Foggo, A; Jeffery, A; Jones, B; Stevens, KN; Webb, D; Whone, A; Wilks, J; Zajicek, J | 1 |
| Bang, CN; Boman, K; Egstrup, K; Greve, AM; Kesäniemi, YA; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Ball, S; Carroll, CB; Creanor, S; Eyre, V; Foggo, A; Stevens, KN; Vickery, J; Webb, D; Webber, M; Whone, A; Wyse, R; Zajicek, J | 1 |
| Bouchal, J; Eder, IE; Jöhrer, K; Kharaishvili, G; Klocker, H; Neuwirt, H; Pitterl, F; Ploner, C; Weber, A | 1 |
| Álvarez, D; Cartier, M; Marino, M; Míguez, C; Muñoz, AE; Pollarsky, F; Romero, G; Salgado, P; Vázquez, H | 1 |
| Fullerton, DA; Gergen, AK; Halpern, AL; Kohtz, PD; Meng, X; Weyant, MJ; White, AM | 1 |
| Bahlmann, E; Chambers, JB; Cramariuc, D; Einarsen, E; Gerdts, E; Midtbo, H | 1 |
| Fugger, J; Gmeiner, M; Herkner, H; Hüttinger, F; Janistyn, W; Pichler, G; Pichler, M; Sajdik, C; Schenk, P; Schmeikal, S; Schügerl, S; Spiel, AO | 1 |
| Camac, ER; Criner, GJ; Voelker, H | 1 |
| Bi, S; Chen, T; Feng, X; Huang, Z; Zhang, L | 1 |
| Bahlmann, E; Boman, K; De Simone, G; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Rossebø, AB; Saeed, S | 1 |
| Ahern, TP; Christiansen, P; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Lash, TL; Sørensen, HT | 1 |
| Bang, CN; Best, P; Boman, K; Egstrup, K; Forman, JL; Greve, AM; Kesäniemi, YA; Pedersen, TR; Rajamannan, NM; Ray, S; Wachtell, K | 1 |
| Bang, CN; Boman, K; Eugen-Olsen, J; Forman, JL; Greve, AM; Hodges, GW; Jeppesen, JL; Kesäniemi, YA; Olsen, MH; Ray, S; Wachtell, K | 1 |
| Cai, W; Jiang, X; Li, T; Sun, J; Wang, C; Yan, F; Zheng, J | 1 |
| Clifton, J; Lang, T; Neher, J; Safranek, S | 1 |
| Araki, D; Kuroda, R; Matsumoto, T; Matsushita, T; Nagai, K; Nishida, K; Tabata, Y; Takayama, K; Tanaka, T | 1 |
| Alexander, DC; Barkhof, F; Cardoso, MJ; Chan, D; Chataway, J; Ciccarelli, O; Eshaghi, A; Greenwood, J; Kievit, RA; Nicholas, J; Nicholas, R; Ourselin, S; Prados, F; Sudre, CH; Thompson, AJ | 1 |
| Cheng, HL; Du, Z; Fan, J; Fan, Y; Gao, Y; Li, L; Li, T; Luo, C; Ma, L; Niu, L; Quan, Z; Sun, W; Wu, X; Yuan, M | 1 |
| Arnon, R; Cork, E; Dolinger, M; Ferguson, E; Iverson, A; Prasun, P; Ward, SC | 1 |
| Chao, YL; Hong, CY; Hou, KL; Kok, SH; Lai, EH; Lee, MS; Lin, LD; Lin, SK; Wang, JS; Yang, H | 1 |
| Gerdts, E; Gohlke-Bärwolf, C; Jander, N; Minners, J; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Cirillo, G; Tedeschi, G; Tessitore, A; Todisco, V | 1 |
| Baiano, S; Barra, A; Buommino, E; De Cicco, R; De Filippis, A; Morelli, F; Spampanato, C; Zanfardino, M | 1 |
| Ching, JK; Ju, JS; Margeta, M; Pittman, SK; Weihl, CC | 1 |
| Ikemori, A; Kimura, K | 1 |
| Aung, KZ; Baird, PN; Busija, L; Dimitrov, PN; Guymer, RH; Lim, L; Makeyeva, GA; Richardson, AJ; Robman, LD; Varsamidis, M | 1 |
| Barbosa, CP; Bersani-Amado, CA; Cuman, RK; da Silva, LG; Grespan, R; Hernandes, L; Ritter, AM | 1 |
| Agodoa, L; Baigent, C; Cass, A; Craig, JC; de Zeeuw, D; Emberson, J; Feldt-Rasmussen, B; Fellström, B; Haynes, R; Herrington, WG; Landray, MJ; Levin, A; Lewis, D; Reith, C; Walker, R; Wheeler, DC | 1 |
| Brewer, T; Buchholz, TA; Debeb, BG; Hortobágyi, GN; Lacerda, L; Larson, R; Li, L; Liu, D; Masuda, H; Reddy, JP; Ueno, NT; Woodward, WA; Xu, W | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Frazee, SG; Garavaglia, SB; Jackevicius, CA; Krumholz, HM; Levin, R; Novshadian, H; Ross, JS; Stettin, G | 1 |
| Agmadova, ZM; Kallaeva, AN | 1 |
| Basta, N; Bolin, K; Busch-Sørensen, M; Egstrup, K; Emneus, M; Green, A; Iachina, M; Kent, C; Kesäniemi, YA; McNally, R; Pedersen, TR; Ramey, DR; Ray, S; Stavem, K; Willenheimer, R | 1 |
| Aisen, PS; Donohue, MC; Edland, SD; Galasko, D; Moghadam, SH; Petersen, RC; Rissman, RA; Roe, AD; Sano, M; Sun, CK; Thomas, RG | 1 |
| Bahlmann, E; Boman, K; Chambers, JB; Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Pedersen, TR; Rogge, BP | 1 |
| Alves-Júnior, MJ; Anhê, GF; de Moraes Schenka, NG; De Souza, PC; de Souza, VB; Hyslop, S; Jampietro, J; Rennó, AL; Rocha, RM; Schenka, AA; Soares, FA; Vassallo, J | 1 |
| Adomat, HH; Cox, ME; Ghaffari, M; Gordon, JA; Guns, ES; Guo, Y; Klassen, TL; Midha, A; Szeitz, A; Wasan, KM | 1 |
| Arnold, RS; Petros, JA; Sun, CQ; Sun, Q | 1 |
| Baigent, C; Cass, A; Emberson, J; Gray, A; Haynes, R; Herrington, W; Landray, MJ; Mihaylova, B; Morton, RL; Schlackow, I; Staplin, N | 1 |
| Alexopoulos, D; Apostolakis, E; Hahalis, G; Koniari, I; Mavrilas, D; Papadaki, H; Papadimitriou, E; Papalois, A; Poimenidi, E; Xanthopoulou, I | 1 |
| Wang, D; Yin, H; Yuan, Z | 1 |
| Barthwal, MK; Dikshit, M; Farooqui, M; Jain, M; Kanshana, JS; Khanna, V; Kumar, S; Misra, A; Singh, V | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Fleming, TR | 1 |
| Otto, CM | 1 |
| Baird, PN; Dimitrov, PN; Guymer, RH; Lim, LL; Robman, L; Varsamidis, M; Vingrys, AJ | 1 |
| Pedersen, TR | 2 |
| Fee, WH | 1 |
| Porat, G | 1 |
| Pazianas, M | 1 |
| Chonchol, M; Cook, T; Huskey, J; Kendrick, J; Kjekshus, J; Lindenfeld, J; Pedersen, T; Targher, G | 1 |
| Fan, YH; Lam, WW; Mok, VC; Ng, PW; Tsoi, TH; Wong, A; Wong, KS; Yeung, V | 1 |
| Chen, MH; Hong, CY; Hou, KL; Kok, SH; Lee, YL; Lin, SK; Lin, YT; Wang, CC | 1 |
| Chen, XY; Lam, WW; Leung, TW; Liu, R; Mok, VC; Ng, PW; Soo, Y; Tsoi, TH; Wong, A; Wong, KS; Yeung, V | 1 |
| Hausenloy, DJ; Yellon, DM | 1 |
| Cioffi, G; Cramariuc, D; Devereux, RB; Gerdts, E; Ray, S; Rieck, AE; Staal, EM; Wachtell, K | 1 |
| Dumesnil, JG; Pibarot, P | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Feng, JB; Ji, XP; Jiang, H; Liu, CX; Liu, Y; Lu, XT; Wang, R; Wu, YL; Xu, XS; Zhang, C; Zhang, L; Zhang, Y; Zhao, YX | 1 |
| Kappagoda, CT; Karalliedde, LD | 1 |
| Chi, SC; Kwong, YY; Lam, DS; Leung, DY; Li, FC; Tham, CC | 1 |
| Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM | 1 |
| Chang, CC; Hong, CY; Hou, KL; Hsiao, M; Kok, SH; Lai, EH; Liang, PC; Lin, SK; Wang, JS; Yang, H | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| Kim, SH; Lee, BS; Lee, ES; Lee, JY; Moon, DW; Park, JE | 1 |
| Chambers, JB; Viljoen, A; Wierzbicki, AS | 1 |
| Carabello, BA | 1 |
| Chu, W; Fu, JH; Lam, W; Mok, V; Ng, PW; Tsoi, TH; Wong, A; Wong, KS; Xiong, Y; Yeung, V | 1 |
| Biesenbach, P; Gremmel, T; Hörl, WH; Kain, R; Säemann, MD | 1 |
| Boman, K; Brudi, P; Egstrup, K; Gohlke-Baerwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Pedersen, TR; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Klein, BE | 1 |
| Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U | 1 |
| Huang, C; Liu, Z; Shen, Z; Wang, Z; Zhu, J | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, C; Pedersen, TR; Ray, S; Rossebø, AB; Skjærpe, T; Wachtell, K; Willenheimer, R | 1 |
| Benowitz, NL; Breazna, A; DeMicco, DA; Frey, P; Pipe, A; Samuels, L; Waters, DD; Wun, CC | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Jander, N; Kesäniemi, YA; Malbecq, W; Minners, J; Neumann, FJ; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, A; Skjærpe, T; Wachtell, K; Willenheimer, R | 1 |
| Alique, M; Badimon, JJ; Cimmino, G; Connolly, TM; Feuerstein, G; Fuster, V; Giannarelli, C; Ibanez, B; Ruiz, JM; Zafar, MU | 1 |
| Aisen, PS; Bell, KL; Galasko, D; Galvin, JE; Sano, M; Thomas, RG; van Dyck, CH | 1 |
| Aktas, E; Gocun, PU; Sener, E | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y | 1 |
| Garcia-Garcia, HM; Okamura, T; Serruys, PW; Shin, ES | 1 |
| Bai, W; Li, H; Zheng, X; Zhou, L | 1 |
| Gugssa, SA; Johnston, JC | 1 |
| Yan, H; Zhang, W | 1 |
| Bea, F; Bennett, B; Blessing, E; Levitz, M; Rosenfeld, ME; Wallace, EP | 1 |
| Harman, SM; Hecht, HS | 1 |
| Asztalos, BF; Batista, M; Brown, GB; Cox, CE; Dallal, GE; Horvath, KV; Morse, JS; Schaefer, EJ | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Hosoda, S; Kaburagi, T; Kitabatake, A; Mizuno, K; Nakamura, H; Ohashi, Y; Tochihara, T | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC | 1 |
| Krane, V; Wanner, C | 1 |
| Clemen, CS; Dodel, R; Klockgether, T; Lütjohann, D; Spottke, EA; Urbach, H; von Bergmann, K | 1 |
| Bhatt, DL; Karha, J | 1 |
| Ichimaru, N; Imamura, R; Matsumiya, K; Moriyama, T; Namba, Y; Nonomura, N; Okuyama, A; Shi, Y; Takahara, S; Toki, K | 1 |
| Bellasi, A; Raggi, P | 1 |
| Christensen, M; Greco, A; Lipschutz, JH; Madaio, MP; Snyder, RW; Su, AW | 1 |
| Gadoth, N; Meiner, V; Siman-Tov, T | 1 |
| Abbate, M; Banfi, C; Bellosta, S; Brioschi, M; Canavesi, M; Gelosa, P; Gianella, A; Guerrini, U; Mussoni, L; Nobili, E; Remuzzi, G; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C | 1 |
| Allen, C; Boman, K; Chambers, J; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, VA; Malbecq, W; Nienaber, C; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Archer, SL; Bonnet, S; Haromy, A; McMurtry, MS; Michelakis, ED | 1 |
| Danesh, FR; Kolavennu, V; Peng, H; Wang, Y; Zeng, L | 1 |
| Padial, LR | 1 |
| Shal'nev, VI | 1 |
| Watson, KE | 1 |
| D'Costa, D; Dorrian, S; Mahmoud, K | 1 |
| Abrahamson, D; Detrano, RC; Franklin, SS; Henein, N; Kashyap, ML; Kukes, G; Rosenzweig, B; Teng, W; Willner, R; Wong, ND | 1 |
| Kroon, AA; Stalenhoef, AF; van Asten, WN | 1 |
| Benesch, L; Bestehorn, HP; Betz, P; Blümchen, G; Claus, J; Kappenberger, L; Mathes, P; Neiss, A; Rensing, UF; Roskamm, H; Schemeitat, K; Wieland, H | 1 |
| Angelin, B; Juliusson, G; Vitols, S | 1 |
| Buller, C; Burton, JR; Montague, TJ; Plante, S; Teo, KK; Yokoyama, S | 1 |
| Cook, TJ; Haghfelt, T; Kjekshus, J; Musliner, TA; Olsson, AG; Pedersen, TR; Pyörälä, K; Tobert, JA | 1 |
| Faergeman, O; Kjekshus, J; Olsson, AG; Pedersen, TR; Pyörälä, K | 1 |
| Banks, T | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Brown, WV | 1 |
| Dickstein, K; Hegland, O; Larsen, JP | 1 |
| Caldwell, SH; Hespenheide, EE; von Borstel, RW | 1 |
| Fujigaki, Y; Hishida, A; Ikegaya, N; Suzuki, H; Togawa, A; Yonemura, K | 1 |
| Chen, YT; Lee, WJ; Sheu, WH | 1 |
| Christenson, JT | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Kumar, A; Misra, A; Pandey, RM; Sen, K | 1 |
16 review(s) available for simvastatin and Disease Exacerbation
| Article | Year |
|---|---|
Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study.
Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Azetidines; Calcinosis; Comorbidity; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypertension; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Simvastatin; Treatment Outcome | 2013 |
[Clinical significance of treatment for dyslipidemia in CKD].
Topics: Azetidines; Cardiovascular Diseases; Cholesterol; Disease Progression; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Kidney Tubules; Lipoproteins; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2013 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Risk Factors; Risk Reduction Behavior; Simvastatin; United Kingdom | 2009 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
Aortic stenosis and lipids: does intervention work?
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Biomarkers, Pharmacological; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Simvastatin; Stress, Physiological | 2010 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2011 |
Syphilitic aortic aneurysm with spastic paraparesis: a novel presentation and review of the literature.
Topics: Aorta, Thoracic; Aortic Aneurysm, Thoracic; Atenolol; Disease Outbreaks; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Paraparesis, Spastic; Penicillins; Simvastatin; Spinal Cord Compression; Syphilis; Time Factors | 2012 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
[Atherosclerosis imaging to assess plaque progression].
Topics: Adult; Aged; Animals; Aortic Diseases; Arteriosclerosis; Calcinosis; Cardiovascular Diseases; Carotid Artery Diseases; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Cost-Benefit Analysis; Disease Progression; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Time Factors; Tomography, X-Ray Computed | 2005 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
What is the evidence in favor of low-dose statin therapy in 2008?
Topics: Cardiovascular Diseases; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Assessment; Simvastatin; Treatment Outcome | 2008 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
46 trial(s) available for simvastatin and Disease Exacerbation
| Article | Year |
|---|---|
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
Topics: Disease Progression; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Simvastatin; State Medicine; Treatment Outcome | 2022 |
Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Asymptomatic Diseases; Biomarkers; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Time Factors; Treatment Outcome | 2019 |
Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
Topics: Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Interviews as Topic; Male; Middle Aged; Neurologic Examination; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Simvastatin | 2019 |
Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver Injury.
Topics: Argentina; Cardiovascular Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Middle Aged; Myalgia; Outcome and Process Assessment, Health Care; Risk Assessment; Severity of Illness Index; Simvastatin | 2021 |
Higher Acceleration/Ejection Time Ratio Predicts Impaired Outcome in Aortic Valve Stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prognosis; Prospective Studies; Severity of Illness Index; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study.
Topics: Disease Progression; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Simvastatin | 2021 |
Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Norway; Prognosis; Prospective Studies; Risk Factors; Simvastatin; Stroke Volume; Survival Rate; Sweden; Ventricular Function, Left | 2017 |
Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Survival Rate; Treatment Outcome | 2018 |
Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Topics: Aged; Anticholesteremic Agents; Aorta; Aortic Valve Stenosis; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Constriction, Pathologic; Disease Progression; Ezetimibe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptors, Urokinase Plasminogen Activator; Risk Factors; Simvastatin | 2018 |
Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Apolipoprotein E2; Complement Factor H; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular Degeneration; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Risk Factors; Simvastatin | 2013 |
Effects of lowering LDL cholesterol on progression of kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Renal Dialysis; Simvastatin; Treatment Outcome | 2014 |
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Registries; Retrospective Studies; Risk Assessment; Simvastatin; Survival Rate; Time Factors | 2014 |
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Biomarkers; Blood Chemical Analysis; Cognitive Dysfunction; Disease Progression; Donepezil; Female; Heterozygote; Humans; Indans; Longitudinal Studies; Male; Nootropic Agents; Peptide Fragments; Piperidines; Severity of Illness Index; Simvastatin; Vitamin E | 2015 |
Sex differences in cardiovascular outcome during progression of aortic valve stenosis.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Norway; Prognosis; Sex Distribution; Sex Factors; Simvastatin; Survival Rate; Systole; Treatment Outcome; Ventricular Function, Left | 2015 |
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Topics: Aged; Anticholesteremic Agents; Disease Progression; Educational Status; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Simvastatin; Vascular Diseases | 2016 |
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome | 2008 |
Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS).
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular Degeneration; Male; Middle Aged; Prospective Studies; Simvastatin; Surveys and Questionnaires; Treatment Outcome; Visual Acuity | 2008 |
Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Aged; Coronary Disease; Diet; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Placebos; Scandinavian and Nordic Countries; Simvastatin; Treatment Outcome | 2009 |
Effects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study.
Topics: Aged; Brain Mapping; Cerebral Arteries; Cerebral Cortex; Dementia, Vascular; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers, Myelinated; Placebos; Severity of Illness Index; Simvastatin; Treatment Outcome | 2009 |
Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study.
Topics: Aged; Constriction, Pathologic; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Male; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Severity of Illness Index; Simvastatin; Treatment Outcome | 2009 |
Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Europe; Ezetimibe, Simvastatin Drug Combination; Female; Hemodynamics; Humans; Hypolipidemic Agents; Logistic Models; Male; Middle Aged; Myocardial Contraction; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Sensitivity and Specificity; Simvastatin; Systole; Treatment Outcome; United States; Ventricular Dysfunction, Left | 2009 |
Simvastatin and disease stabilization in normal tension glaucoma: a cohort study.
Topics: Aged; Anticholesteremic Agents; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intraocular Pressure; Low Tension Glaucoma; Male; Prospective Studies; Simvastatin; Tonometry, Ocular; Vision Disorders; Visual Field Tests; Visual Fields | 2010 |
The SEAS Trial.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2010 |
Effects of statins on progression of subclinical brain infarct.
Topics: Aged; China; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Middle Aged; Odds Ratio; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2010 |
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Apolipoproteins B; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Simvastatin; Time Factors | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2010 |
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Treatment Outcome | 2010 |
Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Smoking; Survival Rate; Treatment Outcome; United States | 2011 |
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Severity of Illness Index; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2011 |
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Cholinesterase Inhibitors; Cognition; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver Function Tests; Male; Neuropsychological Tests; Nootropic Agents; Simvastatin; Treatment Outcome | 2011 |
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression; Electrophoresis, Agar Gel; Female; Humans; Lipids; Lipoproteins, HDL; Male; Middle Aged; Niacin; Particle Size; Radiography; Simvastatin; Treatment Outcome; Vitamins | 2003 |
A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Diet; Disease Progression; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Odds Ratio; Prospective Studies; Simvastatin; Treatment Outcome | 2004 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Creatine Kinase; Creatine Kinase, MM Form; Creatinine; Diabetic Nephropathies; Disease Progression; Feasibility Studies; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isoenzymes; Kidney Diseases; Kidney Transplantation; Lipids; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Renal Dialysis; Renal Replacement Therapy; Simvastatin; Single-Blind Method; Thrombophilia; Treatment Outcome | 2005 |
Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
Topics: Adult; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Pilot Projects; Prognosis; Simvastatin; Tacrolimus; Time Factors; Treatment Outcome | 2005 |
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Blood Flow Velocity; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Simvastatin; Stroke Volume; Treatment Outcome; Triglycerides; Ventricular Function, Left | 2007 |
[The effects of early application of simvastatin on C-reactive protein level, blood lipids, and the clinical course of acute coronary syndrome].
Topics: Acute Coronary Syndrome; C-Reactive Protein; Disease Progression; Humans; Hypolipidemic Agents; Lipoproteins; Simvastatin | 2007 |
Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS).
Topics: Aged; Anticholesteremic Agents; Calcium; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Felodipine; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Tomography, X-Ray Computed | 1995 |
Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Enzyme Inhibitors; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Peripheral Vascular Diseases; Simvastatin | 1996 |
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Treatment Outcome | 1997 |
Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Topics: Adult; Aged; B-Lymphocytes; Cell Division; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukemia, Lymphoid; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Mitogens; Pravastatin; Simvastatin; Thymidine; Tumor Cells, Cultured | 1997 |
Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Enalapril; Female; Humans; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Treatment Outcome; Ventricular Function, Left | 1997 |
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Disease Progression; Heart Failure; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Simvastatin; Survival Analysis | 1997 |
Improvement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Disease Progression; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides; Vasodilation | 2001 |
Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease.
Topics: Aged; Anticholesteremic Agents; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Simvastatin | 2001 |
Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia.
Topics: Blood Glucose; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fundus Oculi; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macular Degeneration; Photography; Placebos; Simvastatin; Visual Acuity | 2002 |
68 other study(ies) available for simvastatin and Disease Exacerbation
| Article | Year |
|---|---|
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones | 2021 |
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Topics: Aged; Benzamides; Biosynthetic Pathways; Cancer-Associated Fibroblasts; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Culture Media, Conditioned; Disease Progression; Drug Resistance, Neoplasm; Extracellular Matrix; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Models, Biological; Molecular Sequence Annotation; Nitriles; Phenotype; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Simvastatin; Spheroids, Cellular; Up-Regulation | 2020 |
Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Animals; Atorvastatin; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Random Allocation; Signal Transduction; Simvastatin; Toll-Like Receptor 4; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life.
Topics: Aged; Azithromycin; Disease Progression; Female; Follow-Up Studies; Health Surveys; Hospitalization; Humans; Male; Middle Aged; Patient Acuity; Prognosis; Pulmonary Disease, Chronic Obstructive; Quality of Life; Simvastatin; Spirometry | 2021 |
A new in vivo method to retard progression of intervertebral disc degeneration through stimulation of endogenous stem cells with simvastatin.
Topics: Animals; Anticholesteremic Agents; Cell Differentiation; Cell Movement; Cells, Cultured; Disease Progression; Glucose Transport Proteins, Facilitative; Humans; Hypoxia-Inducible Factor 1; Intervertebral Disc; Intervertebral Disc Degeneration; Mesenchymal Stem Cells; Simvastatin; Stem Cell Transplantation; Stem Cells; Wound Healing | 2017 |
Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.
Topics: Adrenergic beta-Antagonists; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cardiotonic Agents; Cyclooxygenase 2 Inhibitors; Databases, Factual; Denmark; Digoxin; Disease Progression; Estrogen Antagonists; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasm Recurrence, Local; Platelet Aggregation Inhibitors; Prognosis; Selective Serotonin Reuptake Inhibitors; Simvastatin; Tamoxifen | 2018 |
Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma.
Topics: Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Humans; MicroRNAs; Salivary Gland Neoplasms; Simvastatin; Treatment Outcome | 2018 |
Clinical Inquiries. Do statins alter the risk or progression of dementia?
Topics: Adult; Aged; Aged, 80 and over; Cognition; Dementia; Disease Progression; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; United States; United States Food and Drug Administration | 2018 |
Attenuation of osteoarthritis progression in mice following intra-articular administration of simvastatin-conjugated gelatin hydrogel.
Topics: Animals; Autophagy; Biomarkers; Cells, Cultured; Chondrocytes; Disease Progression; Gelatin; Hydrogels; Injections, Intra-Articular; Male; Mice, Inbred C57BL; Osteoarthritis; Simvastatin | 2019 |
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.
Topics: Adult; Atrophy; Brain; Causality; Cholesterol; Clinical Trials as Topic; Disease Progression; Humans; Middle Aged; Models, Statistical; Multiple Sclerosis, Chronic Progressive; Simvastatin | 2019 |
Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1.
Topics: Adult; Aged; Androgen Receptor Antagonists; Caveolin 1; Cell Line, Tumor; Cell Movement; Cholesterol; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Simvastatin; Survival Analysis; Up-Regulation | 2019 |
Lathosterolosis: An Extremely Rare Inherited Condition Associated With Progressive Liver Disease.
Topics: Abnormalities, Multiple; Child; Diagnosis, Differential; Disease Progression; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Oxidoreductases Acting on CH-CH Group Donors; Simvastatin; Steroid Metabolism, Inborn Errors | 2019 |
Simvastatin suppresses osteoblastic expression of Cyr61 and progression of apical periodontitis through enhancement of the transcription factor Forkhead/winged helix box protein O3a.
Topics: 3T3 Cells; Alveolar Bone Loss; Animals; Cell Line; Chemokine CCL2; Chemotaxis; Cysteine-Rich Protein 61; Disease Models, Animal; Disease Progression; Forkhead Box Protein O3; Forkhead Transcription Factors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Osteoblasts; Periapical Periodontitis; Radiography, Dental, Digital; Rats; Rats, Sprague-Dawley; Simvastatin; Tumor Necrosis Factor-alpha | 2013 |
Clinical reasoning: a 62-year-old man with right wrist drop.
Topics: Blepharoptosis; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Evoked Potentials; Fingers; Functional Laterality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Movement Disorders; Myasthenia Gravis; Simvastatin; Wrist | 2013 |
Simvastatin reduces melanoma progression in a murine model.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholesterol; Disease Progression; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanoma, Experimental; Mice; Mice, Inbred C57BL; RNA-Binding Proteins; Simvastatin; Skin Neoplasms; Survival; Survival Rate; Wound Healing | 2013 |
Increased autophagy accelerates colchicine-induced muscle toxicity.
Topics: Animals; Autophagy; Colchicine; Disease Progression; Humans; Lysosomal Storage Diseases; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Diseases; Phagosomes; Simvastatin; Up-Regulation; Vacuoles | 2013 |
Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis; Azetidines; Cartilage, Articular; Disease Progression; Drug Therapy, Combination; Ezetimibe; Flow Cytometry; Freund's Adjuvant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Rats; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
Topics: Adult; Aged; Cell Differentiation; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Female; Humans; Inflammatory Breast Neoplasms; Kaplan-Meier Estimate; Mastectomy; MCF-7 Cells; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Proportional Hazards Models; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Simvastatin; Spheroids, Cellular; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Disease Progression; Ezetimibe; Female; Humans; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; United States | 2014 |
[Special characteristics of progression of myocardial remodeling in patients with various forms of unstable angina].
Topics: Aged; Angina, Unstable; Aspirin; Benzopyrans; Cardiovascular Agents; Disease Progression; Drug Therapy, Combination; Echocardiography, Doppler; Ethanolamines; Female; Heart Failure; Humans; Male; Middle Aged; Nebivolol; Outcome Assessment, Health Care; Perindopril; Platelet Aggregation Inhibitors; Prognosis; Severity of Illness Index; Simvastatin; Time Factors; Ventricular Remodeling | 2014 |
Decreased expression of stem cell markers by simvastatin in 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antigens, CD; Biomarkers; Biomarkers, Tumor; Carcinogens; Disease Progression; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mammary Neoplasms, Experimental; Necrosis; Neoplastic Stem Cells; Rats; Rats, Sprague-Dawley; Simvastatin | 2015 |
Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
Topics: Administration, Oral; Androgens; Animals; Cell Line, Tumor; Cell Proliferation; Cholesterol; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Simvastatin; Xenograft Model Antitumor Assays | 2016 |
A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Disease Progression; DNA, Mitochondrial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mutation; Prostatic Neoplasms; Simvastatin | 2015 |
Inhibition of Atherosclerosis Progression, Intimal Hyperplasia, and Oxidative Stress by Simvastatin and Ivabradine May Reduce Thoracic Aorta's Stiffness in Hypercholesterolemic Rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Benzazepines; Diet, Atherogenic; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperplasia; Ivabradine; Male; Neointima; Oxidative Stress; Plaque, Atherosclerotic; Rabbits; Simvastatin; Vascular Stiffness | 2016 |
Multiple drilling combined with simvastatin versus multiple drilling alone for the treatment of avascular osteonecrosis of the femoral head: 3-year follow-up study.
Topics: Adult; Body Mass Index; Combined Modality Therapy; Decompression, Surgical; Disease Progression; Female; Femur Head; Femur Head Necrosis; Follow-Up Studies; Hip; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteogenesis; Prognosis; Radiography; Reoperation; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome | 2016 |
Progression and Characterization of the Accelerated Atherosclerosis in Iliac Artery of New Zealand White Rabbits: Effect of Simvastatin.
Topics: Angioplasty, Balloon; Animals; Atherosclerosis; Biomarkers; Diet, High-Fat; Disease Models, Animal; Disease Progression; Endothelium, Vascular; Extracellular Matrix; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Macrophages; Male; Plaque, Atherosclerotic; Rabbits; Simvastatin; Time Factors; Vascular Remodeling; Vasoconstriction; Vasodilation | 2017 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Identifying and addressing safety signals in clinical trials.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Calcific aortic stenosis--time to look more closely at the valve.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Blood Flow Velocity; Calcinosis; Disease Progression; Drug Therapy, Combination; Humans; Simvastatin; Ultrasonography | 2008 |
Intensive lipid-lowering therapy for patients with aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
Calcific aortic stenosis.
Topics: Animals; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Ezetimibe; Humans; Models, Biological; Renal Insufficiency, Chronic; Simvastatin | 2009 |
Simvastatin as a novel strategy to alleviate periapical lesions.
Topics: Alveolar Bone Loss; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blotting, Western; Cell Count; Cell Line; Chemokine CCL2; Chemotaxis; Cysteine-Rich Protein 61; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Macrophages; Osteoblasts; Periapical Periodontitis; Radiography, Dental, Digital; Rats; Rats, Sprague-Dawley; Simvastatin; Tumor Necrosis Factor-alpha | 2009 |
Aortic stenosis: look globally, think globally.
Topics: Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Drug Combinations; Echocardiography, Doppler; Ezetimibe, Simvastatin Drug Combination; Hemodynamics; Humans; Hypolipidemic Agents; Myocardial Contraction; Predictive Value of Tests; Risk Assessment; Risk Factors; Simvastatin; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Aortic Rupture; Atherosclerosis; Biomarkers; Catheterization; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Gene Expression Regulation; Gene Transfer Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Inflammation Mediators; Lipids; Male; Rabbits; RNA, Messenger; Simvastatin; Time Factors; Tumor Suppressor Protein p53; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional; Viper Venoms | 2009 |
The challenge of traditional Chinese medicines for allopathic practitioners.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Aortic Rupture; Atherosclerosis; Biomarkers; Cardiovascular Agents; Complementary Therapies; Disease Progression; Drugs, Chinese Herbal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Simvastatin | 2009 |
Combined hyperlipidemia in patients with lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2010 |
Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: a therapeutic benefit for arthritis.
Topics: Animals; Anticholesteremic Agents; Arthritis, Experimental; Cell Line, Tumor; Cells, Cultured; Chemokine CCL2; Cyclic AMP Response Element-Binding Protein; Cysteine-Rich Protein 61; Cytokines; Disease Models, Animal; Disease Progression; Humans; Injections, Intra-Articular; Male; Osteoblasts; Rats; Rats, Sprague-Dawley; Simvastatin; Treatment Outcome | 2011 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Multiplex coherent anti-stokes Raman spectroscopy images intact atheromatous lesions and concomitantly identifies distinct chemical profiles of atherosclerotic lipids.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Azo Compounds; Brachiocephalic Trunk; Coloring Agents; Crystallization; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunohistochemistry; Lipid Metabolism; Lipids; Male; Mice; Mice, Knockout; Microspectrophotometry; Molecular Structure; Reproducibility of Results; Simvastatin; Spectrum Analysis, Raman; Staining and Labeling; Time Factors | 2010 |
Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Austria; Benzimidazoles; Biopsy; Biphenyl Compounds; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Disease Progression; Embolism, Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Malignant; Kidney; Male; Middle Aged; Proteinuria; Simvastatin; Tetrazoles | 2010 |
Reduction in risk of progression of diabetic retinopathy.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Simvastatin | 2010 |
Simvastatin prevents ERK activation in myocardial hypertrophy of spontaneously hypertensive rats.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Blotting, Western; Body Weight; Disease Progression; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Myocardium; Rats; Rats, Inbred SHR; Rats, Wistar; Signal Transduction; Simvastatin; Time Factors | 2010 |
Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Chemokine CCL2; Cyclooxygenase 2; Disease Progression; Drug Combinations; Drug Synergism; Indazoles; Liver X Receptors; Magnetic Resonance Angiography; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Rabbits; Random Allocation; Simvastatin; Thromboplastin; Up-Regulation | 2012 |
Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3.
Topics: Animals; Anti-Inflammatory Agents; Chondrocytes; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Male; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Osteoarthritis, Knee; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical | 2011 |
Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study.
Topics: Aged; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Necrosis; Odds Ratio; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Calcification | 2012 |
Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.
Topics: Alprostadil; Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Cardiovascular Agents; Chemokine CCL2; Cholesterol, Dietary; Cytokines; Daboia; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Fibrosis; Histamine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipid Metabolism; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; RNA, Messenger; Simvastatin; Viper Venoms | 2012 |
Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Blood Glucose; Blood-Retinal Barrier; Body Weight; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Progression; Endothelium, Vascular; Flow Cytometry; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Retinal Vessels; RNA, Messenger; Simvastatin; Stem Cells; Vascular Endothelial Growth Factor A | 2012 |
Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Mice; Mice, Inbred C57BL; Regression Analysis; Simvastatin; Time Factors | 2002 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Statins may slow MS progression.
Topics: Anticholesteremic Agents; Disease Progression; Humans; Multiple Sclerosis; Simvastatin | 2004 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Transplantation; Peritoneal Dialysis; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Simvastatin; Treatment Outcome | 2005 |
Cerebrotendinous xanthomatosis: a treatable ataxia.
Topics: Adult; Cerebellar Ataxia; Cerebellum; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Disease Progression; Electroencephalography; Humans; Magnetic Resonance Imaging; Male; Paraparesis, Spastic; Peripheral Nervous System Diseases; Simvastatin; Treatment Outcome; Xanthomatosis, Cerebrotendinous | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Simvastatin protection against acute immune-mediated glomerulonephritis in mice.
Topics: Acute Disease; Animals; Blood Urea Nitrogen; Disease Progression; Dose-Response Relationship, Drug; Female; Glomerulonephritis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Mevalonic Acid; Mice; Mice, Inbred C57BL; Proteinuria; Severity of Illness Index; Simvastatin | 2006 |
Could steroids mask the diagnosis of cerebrotendinous xanthomatosis?
Topics: Achilles Tendon; Adult; Brain; Chenodeoxycholic Acid; Cholestanetriol 26-Monooxygenase; Cholestanol; Cholesterol; Diagnosis, Differential; Diagnostic Errors; Disease Progression; Down-Regulation; Humans; Male; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prednisone; Simvastatin; Steroid Hydroxylases; Steroids; Treatment Outcome; Up-Regulation; Xanthomatosis, Cerebrotendinous | 2006 |
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.
Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen; Disease Progression; Fibrinogen; Fibrinolysin; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Electron; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Podocytes; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides | 2007 |
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Echocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphorylation; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Simvastatin; Sirolimus | 2007 |
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Collagen Type IV; Diabetic Nephropathies; Disease Progression; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Mesangial Cells; Mice; Mice, Inbred NOD; Protein Kinase Inhibitors; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin | 2008 |
A case of recurrent rapidly progressive lower limb weakness.
Topics: Acute Disease; Aged; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leg; Male; Muscle Weakness; Rhabdomyolysis; Simvastatin | 2008 |
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
Topics: Adult; Aged; Arteriosclerosis; Disease Progression; Female; Humans; Hypolipidemic Agents; Ischemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis?
Topics: American Heart Association; Anticholesteremic Agents; Arteriosclerosis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diet, Vegetarian; Dietary Fats; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Simvastatin; United States | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Effect of simvastatin in preventing progression of carotid artery stenosis.
Topics: Aged; Carotid Artery, Internal; Carotid Stenosis; Disease Progression; Female; Humans; Male; Risk Factors; Simvastatin; Stroke | 2001 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypoglycemic Agents; Liver Cirrhosis; Myositis; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Potential therapeutic effect of simvastatin on progressive renal failure and nephrotic-range proteinuria caused by renal cholesterol embolism.
Topics: Anticholesteremic Agents; Creatinine; Disease Progression; Embolism, Cholesterol; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nephrosis; Proteinuria; Simvastatin; Treatment Outcome | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |